PCVX - Company ID 0001649094
The table below shows Vaxcyte, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$655.58M | -$452.63M | -$296.79M | -$170.60M | -$121.39M | -$46.63M |
| Capital expenditure | $13.71M | $22.43M | $16.06M | $5.84M | $6.55M | $1.16M |
| Investing cash flow | $437.35M | -$2.01B | -$773.31M | $74.58M | -$212.31M | -$1.10M |
| Dividends paid | - | - | - | - |
Vaxcyte, Inc. reported operating cash flow of -$655.58M for fiscal year 2025. That is down 44.8% from -$452.63M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$30.47M (FY 2018) to -$655.58M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.01M | $2.45B | $639.81M | $861.55M | $17.80M | $374.87M |